Patient recruitment comprises one of the most significant initial challenges in any oncology study but engaging and retaining these patients throughout the trial can ultimately be the challenge requiring the most upfront planning and coordination. However, during the initial planning stages of clinical trial implementation, the focus is usually placed predominately on recruitment and not on patient engagement efforts. This lapse undermines retention rates and potentially negatively impacts the patient experience, thereby reducing the possibility of each patient’s participation in future clinical trials.
Everyone is familiar with the phrase, “time is money.” During the planning stages for a new clinical trial, it’s easy to look at timelines for enrollment and make the key focus enrolling the study as quickly as possible to keep costs in check. However, if a study must replace patients, it adds expense for the sponsor and timeline delays. Many modern clinical trials, particularly in oncology, also include a long-term follow-up element. Oncology trial endpoints are sometimes required to track patients for years to record side effects or the impact of future treatments, in addition to overall long-term survival rates. A patient who isn’t adequately engaged will not complete follow-up long term — if they even stay throughout the treatment portion of the study. Consequently, the sponsor’s submission goals could suffer because they don’t have adequate data, necessitating the enrollment of more patients or an additional trial.
Register for this webinar to learn why engaging and supporting oncology patients is no longer optional but vital to ensuring patient retention for the duration of the study — and beyond.
Ashley Herrick, Ph.D., Executive Director, Oncology Program Strategy, Premier Research
Dr. Ashley Herrick provides strategic planning, coordination, knowledge and expertise for Premier Research’s oncology sponsors. She has more than 13 years of experience in oncology clinical trial oversight and drug development. Dr. Herrick holds a doctorate degree in molecular and cellular biology with a focus on hematologic malignancies from Baylor College of Medicine. She is CCRP-certified and is a member of the American Association for Cancer Research and the American Society of Clinical Oncology. She’s also an active volunteer with the Leukemia and Lymphoma Society.Message Presenter
Nicole Carswell, Executive Director, Patient Engagement & Recruitment, Premier Research
Nicole Carswell leverages worldwide emerging technologies to educate and recruit potential patients. Ms. Carswell has over 25 years of clinical experience, including trial optimization, patient recruitment and engagement, and project leadership. She is a recognized leader who believes in empowering teams to maximize organizational success.Message Presenter
Who Should Attend?
Managers and above at biotech and specialty pharma companies with job functions including, but not limited, to:
- Clinical Operations
- Medical Affairs
- Project Management
- Regulatory Affairs
What You Will Learn
In this webinar, participants will learn about:
- How regulators are signaling a trend toward a greater emphasis on patient engagement earlier in the study process, including the FDA’s recently launched Patient Engagement Collaborative
- Strategies sponsors can use to understand and address patients’ needs, including partnering with advocacy groups and incorporating technologies for real-time patient feedback and analysis
- How engaging and supporting patients early in the study process improves study outcomes by contributing to a fuller understanding of the patient disease journey, including both the patient’s treatment and emotional pathway
Premier Research, a clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions. Visit premier-research.com.